<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31441">Fluticasone propionate</z:chebi> is a new <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> with low systemic bioavailability </plain></SENT>
<SENT sid="1" pm="."><plain>This study reports the outcome of a double blind clinical trial comparing oral <z:chebi fb="0" ids="31441">fluticasone propionate</z:chebi> (5 mg four times daily) with placebo for the treatment of active distal <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Sixty patients were treated for four weeks, with assessments at two and four weeks </plain></SENT>
<SENT sid="3" pm="."><plain>One patient was withdrawn when she was found to have <z:e sem="disease" ids="C0002438" disease_type="Disease or Syndrome" abbrv="">amoebiasis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, results are presented for 29 patients who received placebo and 30 who received <z:chebi fb="0" ids="31441">fluticasone propionate</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The two groups were well matched for age, sex, length of history, and extent of disease </plain></SENT>
<SENT sid="6" pm="."><plain>After four weeks of therapy the clinical, sigmoidoscopic, and histological responses were similar in the two groups </plain></SENT>
<SENT sid="7" pm="."><plain>It is concluded that <z:chebi fb="0" ids="31441">fluticasone propionate</z:chebi> (5 mg four times daily) is not effective treatment for active distal <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
</text></document>